Orphazyme A/S Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Orphazyme A/S in the last year. There are currently 2 sell ratings and 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "sell" Orphazyme A/S stock.
View analyst ratings for Orphazyme A/S or view top-rated stocks.

Wall Street analysts have given Orphazyme A/S a "Sell" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Orphazyme A/S wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Orphazyme A/S saw a increase in short interest in May. As of May 28th, there was short interest totaling 35,300 shares, an increase of 141.8% from the May 13th total of 14,600 shares. Based on an average daily volume of 182,600 shares, the days-to-cover ratio is currently 0.2 days.
View Orphazyme A/S's Short Interest.

3 equities research analysts have issued 1-year price targets for Orphazyme A/S's shares. Their forecasts range from $5.00 to $27.00. On average, they anticipate Orphazyme A/S's share price to reach $16.00 in the next year. This suggests a possible upside of 96.3% from the stock's current price.
View analysts' price targets for Orphazyme A/S or view top-rated stocks among Wall Street analysts.

Some companies that are related to Orphazyme A/S include DiaMedica Therapeutics (DMCAF), Olema Pharmaceuticals (OLMA), Dyne Therapeutics (DYN), Theravance Biopharma (TBPH), Ocular Therapeutix (OCUL), Trillium Therapeutics (TRIL), Phathom Pharmaceuticals (PHAT), Vanda Pharmaceuticals (VNDA), CytoDyn (CYDY), Humanigen (HGEN), Dynavax Technologies (DVAX), Pliant Therapeutics (PLRX), Kinnate Biopharma (KNTE), Connect Biopharma (CNTB) and Rhythm Pharmaceuticals (RYTM).
View all of ORPH's competitors.

(ORPH) raised $100 million in an initial public offering (IPO) on Tuesday, September 29th 2020. The company issued 7,600,000 shares at a price of $13.13 per share. BofA Securities, Cowen and Guggenheim Securities served as the underwriters for the IPO and Danske Markets was co-manager.

Orphazyme A/S trades on the NASDAQ under the ticker symbol "ORPH."

Orphazyme A/S's stock is owned by a variety of institutional and retail investors. Top institutional investors include Point72 Asset Management L.P. (0.38%), Millennium Management LLC (0.35%), Caas Capital Management LP (0.06%) and Point72 Hong Kong Ltd (0.01%).

ORPH stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, and Caas Capital Management LP.

ORPH stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., and Point72 Hong Kong Ltd.

Shares of ORPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ORPH stock can currently be purchased for approximately $8.15.

Orphazyme A/S has a market capitalization of $284.86 million. The company earns $-97,010,000.00 in net income (profit) each year or ($3.42) on an earnings per share basis.

Orphazyme A/S employs 141 workers across the globe.

The official website for Orphazyme A/S is www.orphazyme.com.

Orphazyme A/S is headquartered at OLE MAALOES VEJ 3, COPENHAGEN N G7, DK-2200.

Orphazyme A/S's mailing address is OLE MAALOES VEJ 3, COPENHAGEN N G7, DK-2200. The company can be reached via phone at 45 39 17 82 72 or via email at [email protected]